Novo Nordisk to spend more on acquisitions and external innovation

The success of its GLP-1 molecule in recent years has led Novo Nordisk to increase its focus on acquisitions and external drug candidates and companies.

Photo: Novo Nordisk / PR

Novo Nordisk's successful GLP-1 drug is creating new opportunities for the Danish pharmaceutical giant, which has stated it can no longer rely exclusively on drugs developed in-house, Danish financial daily Børsen reports.

In an interview with Endpoints News, CEO Lars Fruergaard Jørgensen says that Novo Nordisk will continue to make investments over the next year.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs